消化管間質腫瘍（GIST）治療の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D005-00432 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール • 産業分類：医療・製薬

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、消化管間質腫瘍（GIST）治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。消化管間質腫瘍（GIST）治療の種類別市場規模（手術、標的療法、放射線療法、化学療法、アブレーション、塞栓術、その他）、用途別市場規模（病院、クリニック、外来手術センター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、Boston Biomedical、Immunicum、Bayer、Arog Pharmaceuticals、Novartis、Natco Pharma、AB Science、Roche、Sun Pharmaceutical ・地域別グローバル市場分析 2015年-2020年 ・消化管間質腫瘍（GIST）治療の北米市場（アメリカ、カナダ、メキシコ） ・消化管間質腫瘍（GIST）治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・消化管間質腫瘍（GIST）治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・消化管間質腫瘍（GIST）治療の南米市場（ブラジル、アルゼンチン） ・消化管間質腫瘍（GIST）治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：手術、標的療法、放射線療法、化学療法、アブレーション、塞栓術、その他 ・用途別分析：病院、クリニック、外来手術センター、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論

Market Overview
The global Gastrointestinal Stromal Tumors (GISTs) Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Gastrointestinal Stromal Tumors (GISTs) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Gastrointestinal Stromal Tumors (GISTs) Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Gastrointestinal Stromal Tumors (GISTs) Treatment market has been segmented into:
Surgery
Targeted Therapy
Radiation Therapy
Chemotherapy
Ablation
Embolization
Others

By Application, Gastrointestinal Stromal Tumors (GISTs) Treatment has been segmented into:
Hospitals
Clinics
Ambulatory Surgical Centers
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Gastrointestinal Stromal Tumors (GISTs) Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Gastrointestinal Stromal Tumors (GISTs) Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Gastrointestinal Stromal Tumors (GISTs) Treatment market.

The report offers in-depth assessment of the growth and other aspects of the Gastrointestinal Stromal Tumors (GISTs) Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Gastrointestinal Stromal Tumors (GISTs) Treatment Market Share Analysis
Gastrointestinal Stromal Tumors (GISTs) Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Gastrointestinal Stromal Tumors (GISTs) Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Gastrointestinal Stromal Tumors (GISTs) Treatment sales, revenue and market share for each player covered in this report.

The major players covered in Gastrointestinal Stromal Tumors (GISTs) Treatment are:
Pfizer
Boston Biomedical
Immunicum
Bayer
Arog Pharmaceuticals
Novartis
Natco Pharma
AB Science
Roche
Sun Pharmaceutical

レポート目次

---

Table of Contents

1 Gastrointestinal Stromal Tumors (GISTs) Treatment Market Overview
1.1 Product Overview and Scope of Gastrointestinal Stromal Tumors (GISTs) Treatment
1.2 Classification of Gastrointestinal Stromal Tumors (GISTs) Treatment by Type
1.2.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Type in 2019
1.2.3 Surgery
1.2.4 Targeted Therapy
1.2.5 Radiation Therapy
1.2.6 Chemotherapy
1.2.7 Ablation
1.2.8 Embolization
1.2.9 Others
1.3 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market by Application
1.3.1 Overview: Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market by Regions
1.4.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Gastrointestinal Stromal Tumors (GISTs) Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Gastrointestinal Stromal Tumors (GISTs) Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Gastrointestinal Stromal Tumors (GISTs) Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Gastrointestinal Stromal Tumors (GISTs) Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Gastrointestinal Stromal Tumors (GISTs) Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Gastrointestinal Stromal Tumors (GISTs) Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Boston Biomedical
2.2.1 Boston Biomedical Details
2.2.2 Boston Biomedical Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Boston Biomedical SWOT Analysis
2.2.4 Boston Biomedical Product and Services
2.2.5 Boston Biomedical Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Immunicum
2.3.1 Immunicum Details
2.3.2 Immunicum Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Immunicum SWOT Analysis
2.3.4 Immunicum Product and Services
2.3.5 Immunicum Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Bayer
2.4.1 Bayer Details
2.4.2 Bayer Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Bayer SWOT Analysis
2.4.4 Bayer Product and Services
2.4.5 Bayer Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Arog Pharmaceuticals
2.5.1 Arog Pharmaceuticals Details
2.5.2 Arog Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Arog Pharmaceuticals SWOT Analysis
2.5.4 Arog Pharmaceuticals Product and Services
2.5.5 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Novartis SWOT Analysis
2.6.4 Novartis Product and Services
2.6.5 Novartis Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 Natco Pharma
2.7.1 Natco Pharma Details
2.7.2 Natco Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Natco Pharma SWOT Analysis
2.7.4 Natco Pharma Product and Services
2.7.5 Natco Pharma Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 AB Science
2.8.1 AB Science Details
2.8.2 AB Science Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 AB Science SWOT Analysis
2.8.4 AB Science Product and Services
2.8.5 AB Science Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.9 Roche
2.9.1 Roche Details
2.9.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Roche SWOT Analysis
2.9.4 Roche Product and Services
2.9.5 Roche Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.10 Sun Pharmaceutical
2.10.1 Sun Pharmaceutical Details
2.10.2 Sun Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Sun Pharmaceutical SWOT Analysis
2.10.4 Sun Pharmaceutical Product and Services
2.10.5 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Gastrointestinal Stromal Tumors (GISTs) Treatment Players Market Share
3.2.2 Top 10 Gastrointestinal Stromal Tumors (GISTs) Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Market Share by Regions
4.2 North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
5 North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries
5.1 North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries (2015-2020)
5.2 USA Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
6 Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries
6.1 Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries (2015-2020)
6.2 Germany Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
6.4 France Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries
7.1 Asia-Pacific Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries (2015-2020)
7.2 China Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
7.5 India Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
8 South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries
8.1 South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries (2015-2020)
8.2 Brazil Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Gastrointestinal Stromal Tumors (GISTs) Treatment by Countries
9.1 Middle East & Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Forecast by Type (2019-2024)
10.3 Surgery Revenue Growth Rate (2015-2025)
10.4 Targeted Therapy Revenue Growth Rate (2015-2025)
10.5 Radiation Therapy Revenue Growth Rate (2015-2025)
10.6 Chemotherapy Revenue Growth Rate (2015-2025)
10.7 Ablation Revenue Growth Rate (2015-2025)
10.8 Embolization Revenue Growth Rate (2015-2025)
10.9 Others Revenue Growth Rate (2015-2025)
11 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Segment by Application
11.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Application (2015-2020)
11.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Ambulatory Surgical Centers Revenue Growth (2015-2020)
11.6 Others Revenue Growth (2015-2020)
12 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size Forecast (2021-2025)
12.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size Forecast (2021-2025)
12.2 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Forecast by Regions (2021-2025)
12.3 North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2021-2025)
12.6 South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Gastrointestinal Stromal Tumors (GISTs) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Pfizer Corporate Information, Location and Competitors
Table 6. Pfizer Gastrointestinal Stromal Tumors (GISTs) Treatment Major Business
Table 7. Pfizer Gastrointestinal Stromal Tumors (GISTs) Treatment Total Revenue (USD Million) (2017-2018)
Table 8. Pfizer SWOT Analysis
Table 9. Pfizer Gastrointestinal Stromal Tumors (GISTs) Treatment Product and Solutions
Table 10. Pfizer Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Boston Biomedical Corporate Information, Location and Competitors
Table 12. Boston Biomedical Gastrointestinal Stromal Tumors (GISTs) Treatment Major Business
Table 13. Boston Biomedical Gastrointestinal Stromal Tumors (GISTs) Treatment Total Revenue (USD Million) (2018-2019)
Table 14. Boston Biomedical SWOT Analysis
Table 15. Boston Biomedical Gastrointestinal Stromal Tumors (GISTs) Treatment Product and Solutions
Table 16. Boston Biomedical Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Immunicum Corporate Information, Location and Competitors
Table 18. Immunicum Gastrointestinal Stromal Tumors (GISTs) Treatment Major Business
Table 19. Immunicum Gastrointestinal Stromal Tumors (GISTs) Treatment Total Revenue (USD Million) (2017-2018)
Table 20. Immunicum SWOT Analysis
Table 21. Immunicum Gastrointestinal Stromal Tumors (GISTs) Treatment Product and Solutions
Table 22. Immunicum Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Bayer Corporate Information, Location and Competitors
Table 24. Bayer Gastrointestinal Stromal Tumors (GISTs) Treatment Major Business
Table 25. Bayer Gastrointestinal Stromal Tumors (GISTs) Treatment Total Revenue (USD Million) (2017-2018)
Table 26. Bayer SWOT Analysis
Table 27. Bayer Gastrointestinal Stromal Tumors (GISTs) Treatment Product and Solutions
Table 28. Bayer Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Arog Pharmaceuticals Corporate Information, Location and Competitors
Table 30. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GISTs) Treatment Major Business
Table 31. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GISTs) Treatment Total Revenue (USD Million) (2017-2018)
Table 32. Arog Pharmaceuticals SWOT Analysis
Table 33. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GISTs) Treatment Product and Solutions
Table 34. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Novartis Corporate Information, Location and Competitors
Table 36. Novartis Gastrointestinal Stromal Tumors (GISTs) Treatment Major Business
Table 37. Novartis Gastrointestinal Stromal Tumors (GISTs) Treatment Total Revenue (USD Million) (2017-2018)
Table 38. Novartis SWOT Analysis
Table 39. Novartis Gastrointestinal Stromal Tumors (GISTs) Treatment Product and Solutions
Table 40. Novartis Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Natco Pharma Corporate Information, Location and Competitors
Table 42. Natco Pharma Gastrointestinal Stromal Tumors (GISTs) Treatment Major Business
Table 43. Natco Pharma Gastrointestinal Stromal Tumors (GISTs) Treatment Total Revenue (USD Million) (2017-2018)
Table 44. Natco Pharma SWOT Analysis
Table 45. Natco Pharma Gastrointestinal Stromal Tumors (GISTs) Treatment Product and Solutions
Table 46. Natco Pharma Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. AB Science Corporate Information, Location and Competitors
Table 48. AB Science Gastrointestinal Stromal Tumors (GISTs) Treatment Major Business
Table 49. AB Science Gastrointestinal Stromal Tumors (GISTs) Treatment Total Revenue (USD Million) (2017-2018)
Table 50. AB Science SWOT Analysis
Table 51. AB Science Gastrointestinal Stromal Tumors (GISTs) Treatment Product and Solutions
Table 52. AB Science Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Roche Corporate Information, Location and Competitors
Table 54. Roche Gastrointestinal Stromal Tumors (GISTs) Treatment Major Business
Table 55. Roche Gastrointestinal Stromal Tumors (GISTs) Treatment Total Revenue (USD Million) (2017-2018)
Table 56. Roche SWOT Analysis
Table 57. Roche Gastrointestinal Stromal Tumors (GISTs) Treatment Product and Solutions
Table 58. Roche Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Sun Pharmaceutical Corporate Information, Location and Competitors
Table 60. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GISTs) Treatment Major Business
Table 61. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GISTs) Treatment Total Revenue (USD Million) (2017-2018)
Table 62. Sun Pharmaceutical SWOT Analysis
Table 63. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GISTs) Treatment Product and Solutions
Table 64. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) by Players (2015-2020)
Table 66. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Share by Players (2015-2020)
Table 67. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) by Regions (2015-2020)
Table 68. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Regions (2015-2020)
Table 69. North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries (2015-2020)
Table 70. North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Countries (2015-2020)
Table 71. Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) by Countries (2015-2020)
Table 72. Asia-Pacific Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) by Countries (2015-2020)
Table 73. South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries (2015-2020)
Table 74. South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Countries (2015-2020)
Table 75. Middle East and Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) by Countries (2015-2020)
Table 76. Middle East and Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Countries (2015-2020)
Table 77. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) by Type (2015-2020)
Table 78. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Share by Type (2015-2020)
Table 79. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Forecast by Type (2021-2025)
Table 80. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Application (2015-2020)
Table 81. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Share by Application (2015-2020)
Table 82. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Forecast by Application (2021-2025)
Table 83. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Gastrointestinal Stromal Tumors (GISTs) Treatment Picture
Figure 2. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Type in 2019
Figure 3. Surgery Picture
Figure 4. Targeted Therapy Picture
Figure 5. Radiation Therapy Picture
Figure 6. Chemotherapy Picture
Figure 7. Ablation Picture
Figure 8. Embolization Picture
Figure 9. Others Picture
Figure 10. Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Application in 2019
Figure 11. Hospitals Picture
Figure 12. Clinics Picture
Figure 13. Ambulatory Surgical Centers Picture
Figure 14. Others Picture
Figure 15. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 16. North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Asia-Pacific Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Middle East and Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 22. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Share by Players in 2019
Figure 23. Global Top 5 Players Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share in 2019
Figure 24. Global Top 10 Players Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share in 2019
Figure 25. Key Players Market Share Trend
Figure 26. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 27. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Regions (2015-2020)
Figure 28. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Regions in 2018
Figure 29. North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 30. Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 31. Asia-Pacific Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 32. South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 33. Middle East and Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 34. North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Countries (2015-2020)
Figure 35. North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Countries in 2019
Figure 36. USA Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 37. Canada Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 38. Mexico Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 39. Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Countries (2015-2020)
Figure 40. Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Countries in 2019
Figure 41. Germany Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 42. UK Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 43. France Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 44. Russia Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 45. Italy Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 46. Asia-Pacific Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Countries (2015-2020)
Figure 47. Asia-Pacific Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Countries in 2019
Figure 48. China Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 49. Japan Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 50. Korea Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 51. India Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 52. Southeast Asia Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 53. South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Countries (2015-2020)
Figure 54. South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Countries in 2019
Figure 55. Brazil Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 56. Argentina Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 57. Middle East and Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Countries (2015-2020)
Figure 58. Middle East and Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Countries in 2019
Figure 59. Saudi Arabia Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 60. UAE Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 61. Egypt Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 62. South Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2015-2020)
Figure 63. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Share by Type (2015-2020)
Figure 64. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Share by Type in 2019
Figure 65. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Share Forecast by Type (2021-2025)
Figure 66. Global Surgery Revenue Growth Rate (2015-2020)
Figure 67. Global Targeted Therapy Revenue Growth Rate (2015-2020)
Figure 68. Global Radiation Therapy Revenue Growth Rate (2015-2020)
Figure 69. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 70. Global Ablation Revenue Growth Rate (2015-2020)
Figure 71. Global Embolization Revenue Growth Rate (2015-2020)
Figure 72. Global Others Revenue Growth Rate (2015-2020)
Figure 73. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Share by Application (2015-2020)
Figure 74. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Share by Application in 2019
Figure 75. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Share Forecast by Application (2021-2025)
Figure 76. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 77. Global Clinics Revenue Growth Rate (2015-2020)
Figure 78. Global Ambulatory Surgical Centers Revenue Growth Rate (2015-2020)
Figure 79. Global Others Revenue Growth Rate (2015-2020)
Figure 80. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 81. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 82. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 83. North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2021-2025)
Figure 84. Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2021-2025)
Figure 85. Asia-Pacific Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2021-2025)
Figure 86. South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2021-2025)
Figure 87. Middle East and Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2021-2025)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel

---